Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Coherus Bio (CHRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,411,742
  • Shares Outstanding, K 69,339
  • Annual Sales, $ 0 K
  • Annual Income, $ -209,340 K
  • 60-Month Beta 3.64
  • Price/Sales 36.93
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.36
  • Prior Year -0.68
  • Growth Rate Est. (year over year) +69.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.55 +50.26%
on 04/24/19
21.18 -3.87%
on 05/22/19
+6.18 (+43.58%)
since 04/23/19
3-Month
12.95 +57.22%
on 04/01/19
21.18 -3.87%
on 05/22/19
+5.62 (+38.13%)
since 02/22/19
52-Week
8.32 +144.71%
on 01/04/19
21.18 -3.87%
on 05/22/19
+5.06 (+33.07%)
since 05/23/18

Most Recent Stories

More News
Amgen (AMGN) Offers to Acquire Drug Discovery Platform

Amgen (AMGN) looks to acquire Nuevolution in an all-cash deal. Nuevolution focuses on discovering small molecule drugs partnering its proprietary platform.

MYL : 19.20 (+0.16%)
LLY : 117.00 (+0.16%)
CHRS : 20.36 (-0.97%)
AMGN : 172.24 (+0.08%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Karyopharm Thera (KPTI , CHRS , REGN , SAGE , BPMC )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CHRS : 20.36 (-0.97%)
KPTI : 6.10 (unch)
REGN : 315.26 (-1.51%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (IRWD , CHRS , MRTX, MGNX , RTRX )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

IRWD : 11.08 (-2.12%)
CHRS : 20.36 (-0.97%)
MRTX : 74.49 (-2.47%)
Watch for Coherus Bioscien to Potentially Pullback After Gaining 3.87% Yesterday

Coherus Bioscien (NASDAQ:CHRS) traded in a range yesterday that spanned from a low of $17.45 to a high of $18.23. Yesterday, the shares gained 3.9%, which took the trading range above the 3-day high...

CHRS : 20.36 (-0.97%)
49.4% Return Seen to Date on SmarTrend Coherus Bioscien Call (CHRS)

SmarTrend identified an Uptrend for Coherus Bioscien (NASDAQ:CHRS) on January 9th, 2019 at $11.23. In approximately 4 months, Coherus Bioscien has returned 49.42% as of today's recent price of $16.78....

CHRS : 20.36 (-0.97%)
Coherus BioSciences (CHRS) Reports Q1 Loss, Tops Revenue Estimates

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 36.96% and 0.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CHRS : 20.36 (-0.97%)
Coherus BioSciences Reports Corporate Highlights and First Quarter 2019 Financial Results

Coherus BioSciences, Inc. ("Coherus" or "the Company", Nasdaq: CHRS), today reviewed corporate highlights and reported financial results for the quarter ended March 31, 2019.

CHRS : 20.36 (-0.97%)
Coherus Bioscien Shares Up 45.5% Since SmarTrend's Buy Recommendation (CHRS)

SmarTrend identified an Uptrend for Coherus Bioscien (NASDAQ:CHRS) on January 9th, 2019 at $11.23. In approximately 4 months, Coherus Bioscien has returned 45.50% as of today's recent price of $16.34....

CHRS : 20.36 (-0.97%)
Coherus BioSciences and Amgen Settle Trade Secrets Action

Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced that Amgen and Coherus have settled the trade secret action brought by Amgen against Coherus that was pending in the Superior Court...

CHRS : 20.36 (-0.97%)
AMGN : 172.24 (+0.08%)
Coherus BioSciences Management to Present at Two Upcoming Investor Healthcare Conferences

Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at two upcoming investor healthcare conferences.

CHRS : 20.36 (-0.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade CHRS with:

Business Summary

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid...

See More

Key Turning Points

2nd Resistance Point 21.10
1st Resistance Point 20.73
Last Price 20.36
1st Support Level 19.80
2nd Support Level 19.23

See More

52-Week High 21.18
Last Price 20.36
Fibonacci 61.8% 16.27
Fibonacci 50% 14.75
Fibonacci 38.2% 13.23
52-Week Low 8.32

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar